Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Call Transcript

Page 5 of 5

Unidentified Analyst: Great. Thanks. And then just one on the PFIC launch. Do you think this will be a lean add-on? Or do you see any need to invest further into the commercial team?

Chris Peetz: I’ll ask Peter to maybe describe some of the launch plans.

Peter Radovich: Yes. We don’t see a need for incremental OpEx for PFIC. It’s straightforward. In fact, the PFIC patients are probably taking care by a subset of the prescribers who’ve prescribed LIVMARLI today for Alagille syndrome.

Unidentified Analyst: Great. I’ll back in queue. Thank you.

Chris Peetz: Thanks for the questions.

Operator: Thank you. . We have no further questions on the line.

Chris Peetz: Great. Thank you, operator. And thank you to everyone for joining today’s call. Hope you have a great day. Bye-bye.

Operator: Thank you. Ladies and gentlemen, this concludes today’s call. Thank you for joining. You may now disconnect your lines.

Follow Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)

Page 5 of 5